We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+17.87%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$39.3M
Cap. Flow
+$15.2M
Cap. Flow %
5.83%
Top 10 Hldgs %
55.54%
Holding
65
New
16
Increased
14
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$6.2M
2
AKAO
Achaogen Inc
AKAO
+$5.75M
3
BMY icon
Bristol-Myers Squibb
BMY
+$5.38M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$5.36M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.71M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$11.6M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$8.18M
3
AERI
Aerie Pharmaceuticals
AERI
+$5.49M
4
GILD icon
Gilead Sciences
GILD
+$5.2M
5
SHPG
Shire pic
SHPG
+$4.72M

Sector Composition

Rank Sector Weight
1 Healthcare 99.69%
2 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STML
26
DELISTED
Stemline Therapeutics, Inc.
STML
$2.81M 1.07%
+330,000
New +$3.01M
ANAB icon
27
AnaptysBio
ANAB
$1.7B
$2.79M 1.07%
+100,500
New +$2.34M
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$2.52M 0.96%
322,436
– –
ONC
29
BeOne Medicines Ltd
ONC
$42.1B
$2.42M 0.93%
+66,041
New +$2.41M
PRTA icon
30
Prothena Corp
PRTA
$467M
$2.34M 0.9%
42,000
– –
GBT
31
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.13M 0.82%
+58,000
New +$1.46M
IONS icon
32
Ionis Pharmaceuticals
IONS
$10.4B
$2.07M 0.79%
+51,500
New +$2.31M
VNDA icon
33
Vanda Pharmaceuticals
VNDA
$329M
$1.9M 0.73%
135,817
– –
NBIX icon
34
Neurocrine Biosciences
NBIX
$15.8B
$1.74M 0.67%
40,264
– –
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$5.12B
$1.71M 0.65%
49,651
-807
-2% -$28.5K
VCYT icon
36
Veracyte
VCYT
$3.64B
$1.56M 0.6%
+170,000
New +$1.39M
SGYP
37
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.45M 0.56%
312,000
– –
NKTR icon
38
Nektar Therapeutics
NKTR
$2.55B
$1.41M 0.54%
4,000
– –
TRIL
39
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.36M 0.52%
221,847
– –
CHRS icon
40
Coherus Oncology
CHRS
$226M
$1.31M 0.5%
+62,000
New +$1.53M
CLVS
41
DELISTED
Clovis Oncology, Inc.
CLVS
$1.27M 0.49%
20,000
-55,000
-73% -$3.34M
ICPT
42
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.26M 0.48%
11,155
-18,400
-62% -$2.15M
HZNP
43
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$1.25M 0.48%
85,000
– –
SAGE
44
DELISTED
Sage Therapeutics
SAGE
$1.21M 0.46%
16,996
– –
AGIO icon
45
Agios Pharmaceuticals
AGIO
$2.05B
$1.17M 0.45%
+20,000
New +$959K
GWPH
46
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.11M 0.43%
9,200
+1,700
+23% +$209K
CALA
47
DELISTED
Calithera Biosciences, Inc
CALA
$1.08M 0.41%
+4,665
New +$806K
ASXC
48
DELISTED
Asensus Surgical, Inc.
ASXC
$1.08M 0.41%
68,391
– –
PTLA
49
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.02M 0.39%
+26,000
New +$828K
IRWD icon
50
Ironwood Pharmaceuticals
IRWD
$701M
$1.01M 0.39%
70,446
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2017 Portfolio in Review

As of Q1 2017, International Biotechnology Trust held 65 positions worth $261M, up 18% from $222M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

International Biotechnology Trust deployed $15.2M of net new capital in Q1 2017, opening 16 new positions and adding to 14 existing holdings. Its largest new stake was Achaogen Inc: 280,038 shares worth $7.07M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was TESARO, Inc., an estimated $11.6M trimmed.

  • International Biotechnology Trust's largest Q1 2017 buy was Achaogen Inc: 280,038 shares worth $7.07M.
  • International Biotechnology Trust added most to Incyte in Q1 2017, an estimated $6.2M increase.
  • International Biotechnology Trust's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $11.6M.
  • International Biotechnology Trust fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $8.18M.
  • International Biotechnology Trust's ten largest holdings make up 56% of its $261M portfolio in Q1 2017.
  • International Biotechnology Trust opened 16 new positions and closed 5 in Q1 2017.
  • International Biotechnology Trust's portfolio value rose 18% quarter-over-quarter to $261M.

Based on International Biotechnology Trust's 13F filing for Q1 2017, filed 2 Mar 2018.